Production (Stage)
NLS Pharmaceutics AG
NLSP
$2.30
$0.2210.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -47.60% | -47.60% | -43.70% | -43.70% | -18.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -62.82% | -62.82% | -72.80% | -72.80% | -37.34% |
| Operating Income | 62.82% | 62.82% | 72.80% | 72.80% | 37.34% |
| Income Before Tax | 101.21% | 101.21% | 73.26% | 73.26% | 41.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 101.21% | 101.21% | 73.26% | 73.26% | 41.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 101.21% | 101.21% | 73.26% | 73.26% | 41.96% |
| EBIT | 62.82% | 62.82% | 72.80% | 72.80% | 37.34% |
| EBITDA | 62.81% | 62.84% | 72.85% | 72.85% | 37.37% |
| EPS Basic | 79.24% | 79.24% | 75.66% | 75.66% | 64.31% |
| Normalized Basic EPS | 82.52% | 82.52% | 75.66% | 75.66% | 59.56% |
| EPS Diluted | 79.24% | 79.24% | 75.66% | 75.66% | 64.31% |
| Normalized Diluted EPS | 82.52% | 82.52% | 75.66% | 75.66% | 59.56% |
| Average Basic Shares Outstanding | 113.53% | 113.53% | 9.87% | 9.87% | 62.64% |
| Average Diluted Shares Outstanding | 113.53% | 113.53% | 9.87% | 9.87% | 62.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |